Quantitative assessment of matrix metalloproteinasis 7 (MMP-7) and tissue inhibitor of MMP-7 (TIMP1) in NSCLC tissue samples Source: Eur Respir J 2006; 28: Suppl. 50, 813s Year: 2006
Serum levels of STR-3 and TIMP-2 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Immunohistochemical studies of COX-2, MMP-9, p53 and VEGF in non-small-cell lung cancer, specifically squamous cell carcinoma and adenocarcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006
Matrix metalloprotease-1 and tissue inhibitor of metalloprotease-1 levels in pleural effusions of different origins Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
The clinical significance of soluble E-cadherin in lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 769s Year: 2006
Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
Prognostic significance of the expressions of Axl and/or Gas6 in patients with completely resected lung adenocarcinoma Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Clinical significance of serum osteopontin levels in lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
CD44v6 expression in tissue of patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
MMP-2 as a marker of human lung carcinoma cells Source: Eur Respir J 2003; 22: Suppl. 45, 224s Year: 2003
The effect of SDF-1/CXCR4 on expression of VEGF and MMP-9 in small cell lung cancer Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012
The effects of hypoxia on the expression of MMP-2, MMP-9 in human lung adenocarcinoma A549 cells Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes? Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
Genes affecting mRNA stability and metalloproteinase inhibitor RECK are down-regulated in patients with COPD Source: Annual Congress 2013 –New insights into epigenetic mechanisms in the lung Year: 2013
MMP-9 and TIMP-1 expression in acute lung injury rats with diabetes Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004
Clinical significance of hypoxia inducible factor-1α and VEGF expression in lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009